Insilico Medicine

First AI-discovered drug enters Phase III trial

Insilico Medicine announced on Tuesday that it dosed the first patient with Rentosertib in GENESIS-IPF-3, marking the first time a drug candidate discovered and designed entirely by generative AI has entered a Phase III clinical trial. The dosing took place…

AI-designed drug reversed aging markers in trial, Insilico says

An experimental drug developed using artificial intelligence reduced biological age by as much as three to four years in patients with a chronic lung disease, according to a new study that marks a milestone in the convergence of AI-driven drug…